美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

DEFIANCE DAILY TARGET 2X LONG HIMS ETF

2.03

+0.910081.25%

盘后：2.00-0.0300-1.48%19:59 EDT

成交量：1.79亿

成交额：3.65亿

市值：1.16亿

市盈率：- -

高：2.21

开：2.18

低：1.85

收：1.12

52周最高：57.00

52周最低：0.8844

股本：5,727.50万

流通股本：5,727.50万

量比：3.94

换手率：311.66%

股息：0.14

股息率：6.96%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%

环球市场播报

BUZZ--美国股票走势-Hims & Hers、Live Nation、NovaBridge

Hims与诺和诺德合作或引发短期逆风——市场快讯

FDA官员Makary表示欣慰：Hims将停止宣传未经批准的复方药物，转而通过与诺和诺德新合作销售FDA批准产品

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/HIMZ"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HIMZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIMZ\",,,,,undefined,":{"symbol":"HIMZ","market":"US","secType":"STK","nameCN":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","latestPrice":2.03,"timestamp":1773086400000,"preClose":1.12,"halted":0,"volume":178501116,"hourTrading":{"tag":"盘后","latestPrice":2,"preClose":2.03,"latestTime":"19:59 EDT","volume":2952427,"amount":6059221.9115,"timestamp":1773100793777,"change":-0.03,"changeRate":-0.014778,"amplitude":0.054187},"delay":0,"changeRate":0.8124999999999997,"floatShares":57275000,"shares":57275000,"eps":0,"marketStatus":"已收盘","change":0.91,"latestTime":"03-09 16:00:00 EDT","open":2.18,"high":2.205,"low":1.8545,"amount":365158804.7953968,"amplitude":0.312946,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1773129600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":1.12,"sharesOutstanding":57385000,"nav":1.11,"aum":63575250,"dividendRate":0.069606,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":2.17,"preClose":1.12,"latestTime":"09:29 EDT","volume":17438587,"amount":37791086.9017759,"timestamp":1773062999999,"change":1.05,"changeRate":0.9375,"amplitude":0.383929},"postHourTrading":{"tag":"盘后","latestPrice":2,"preClose":2.03,"latestTime":"19:59 EDT","volume":2952427,"amount":6059221.9115,"timestamp":1773100793777,"change":-0.03,"changeRate":-0.014778,"amplitude":0.054187},"volumeRatio":3.939266,"impliedVol":2.1603,"impliedVolPercentile":0.9381},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIMZ\",,,,,undefined,":{"symbol":"HIMZ","floatShares":57275000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.939266,"shares":57275000,"dividePrice":0.1413,"high":2.205,"amplitude":0.312946,"preClose":1.12,"low":1.8545,"week52Low":0.8844,"pbRate":"--","week52High":57,"institutionHeld":0,"latestPrice":2.03,"eps":0,"divideRate":0.069606,"volume":178501116,"delay":0,"ttmEps":0,"open":2.18,"prevYearClose":5.79,"prevWeekClose":1.12,"prevMonthClose":0.972,"prevQuarterClose":5.79,"fiveDayClose":1.24,"twentyDayClose":2.71,"sixtyDayClose":9.19},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIMZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-18","symbol":"HIMZ","defaultRemindTime":1773840600000,"type":"split","dateTimestamp":1773806400000,"forFactor":14,"toFactor":1,"ratio":14}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIMZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIMZ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIMZ\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618672446","title":"3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672446","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672446?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 04:48","pubTimestamp":1773089280,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名英伟达收高2.72%，成交313.6亿美元。亿万富豪廖凯原周一再度增持英伟达，将其持股数量翻倍至200万股。　　摩尔维持对博通的“买入”评级，将其目标价从462美元上调至470美元，意味着约42%的上涨空间。　　此外，3月2日，英伟达宣布投资20亿美元并与Lumentum达成多年战略合作，包括数十亿美元采购高端激光元件的承诺，聚焦AI数据中心光学技术。　　该消息公布后，诺和诺德撤销了对该公司的诉讼，标志着双方争端的结束。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqmumf6558599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BKVL7J92.USD","BK4585","LU0154236417.USD","BK4599","BK4532","HIMS","NVO","HMYY","NVOH","BK4007","BK4196","LU1093756325.SGD","BK4588","NVOX","HIMY","HIMZ","IE00BZ1G4Q59.USD","HIYY","LU1093756168.USD"],"gpt_icon":1},{"id":"2618621524","title":"BUZZ--美国股票走势-Hims & Hers、Live Nation、NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621524","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621524?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 21:30","pubTimestamp":1773063020,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4S3ZX1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEM","RAPP","XOMO","UAL","AU","DTIL","HIMY","RLMD","PLD","LU1894683264.USD","HMYY","LU0162691827.USD","PFE","LU2462611646.USD","SATS","VRTL","AAL","BARC.UK","ITT","XOMX","HIMZ","VRT","NEMG","DAL","CAT","LU0170899867.USD","AALG","XOMZ","CDE","NBP","AGH","LYV","COP","HIMS","LITX","SLB","IE00B2Q91V27.USD","COHX","LU0433182093.SGD","LUV","SATG","HL","HIYY","XENE","FCEL","NWMX"],"gpt_icon":1},{"id":"1162171962","title":"Hims与诺和诺德合作或引发短期逆风——市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1162171962","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162171962?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:53","pubTimestamp":1773060828,"startTime":"0","endTime":"0","summary":"早盘8点49分——Hims & Hers Health Inc.股价因诺和诺德终止对其诉讼并达成合作的消息而大幅飙升。根据协议，Hims平台将引入诺和诺德的GLP-1类药物。Truist分析师指出，尽管此举消除了Hims面临的重要法律风险，但合作可能对其短期业务造成冲击。\n作为协议的一部分，Hims将停止销售复合GLP-1药物，而这类药物曾贡献其大部分营收。不过，品牌GLP-1药物的收入持续性显著更高，尤其考虑到Hims的复合药物此前一直面临法律威胁。分析师认为，这一转变可能促使投资者愿意给予Hims更高估值倍数。受此影响，Hims股价在盘前交易中猛涨51%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","IE00BKVL7J92.USD","HIYY","NVOH","HIMZ","BK4196","LU0154236417.USD","HIMS","BK4588","LU1093756168.USD","HIMY","BK4532","BK4585","BK4599","HMYY","NVOX","BK4007"],"gpt_icon":0},{"id":"1109539785","title":"FDA官员Makary表示欣慰：Hims将停止宣传未经批准的复方药物，转而通过与诺和诺德新合作销售FDA批准产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1109539785","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109539785?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:50","pubTimestamp":1773060649,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）官员Makary近日发表声明，对Hims & Hers Health Inc.决定停止推广未经批准的复方药物表示赞赏。该公司将转向通过与新合作伙伴诺和诺德（Novo）建立的合作关系，专门销售获得FDA正式批准的医药产品。\n这一战略调整标志着Hims在合规经营和产品质量管控方面迈出重要一步。通过采用经FDA严格审批的标准化药物，既能保障患者用药安全，又有助于提升企业品牌信誉。与诺和诺德的合作预计将拓宽其合规产品的市场覆盖范围。\n行业观察人士指出，此举可能对在线医疗平台的产品监管合规性产生示范效应。随着监管环境日趋严格，更多企业或将重新评估其复方药物的营销策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","HMYY","HIMY","BK4196","HIMS","HIMZ"],"gpt_icon":0}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/HIMZ\",params:#limit:6,delay:false,,,undefined,":[]}}